The variable splicing factor RBM17 regulates MDS cell proliferation through H3K27la

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Low expression of TMSB10 in bone marrow in MDS patients with T cell large granular lymphocytic proliferation is associated with improved immune tolerance status of T cells and disease prognosis: Clinical data and single-cell sequencing analysis2025
2. 2Targeting ephrin A3 in the bone marrow niche offers a promising therapeutic strategy to impede hematopoietic stem cell maintenance in MDS patients2025
3. 35-azacytidine treatment reshapes clonal structure and alters mutation-dependent splicing in MDS patients2025
4. 4Aberrant cell cycle regulation and osteoblastic differentiation in diamond-blackfan anemia (DBA) mesenchymal stem cells2025
5. 5Transcriptional and splicing dysregulation by U2AF1 mutations contribute to inflammatory and migratory alterations in MDS2025